A human papillomavirus type 16 vaccine by oral delivery of L1 protein
- 30 June 2005
- journal article
- Published by Elsevier in Virus Research
- Vol. 110 (1-2) , 81-90
- https://doi.org/10.1016/j.virusres.2005.02.001
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic PlantsJournal of Virology, 2003
- A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccineInternational Journal of Cancer, 2003
- Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTESGene Therapy, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with Escherichia coli Heat-Labile Enterotoxin Mutant R192G or CpG DNAJournal of Virology, 2001
- Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle VaccineJNCI Journal of the National Cancer Institute, 2001
- Abrogation of Oral Tolerance by Feeding Encapsulated AntigenCellular Immunology, 2000
- Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical CancerThe Journal of Infectious Diseases, 1999
- Natural History of Cervicovaginal Papillomavirus Infection in Young WomenNew England Journal of Medicine, 1998
- Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM,and mucosal IgA antibodiesVirology, 1995